Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Long-Term Investments (2017 - 2023)

vTv Therapeutics' Long-Term Investments history spans 7 years, with the latest figure at $4.4 million for Q3 2023.

  • For Q3 2023, Long-Term Investments fell 28.96% year-over-year to $4.4 million; the TTM value through Sep 2023 reached $4.4 million, down 28.96%, while the annual FY2022 figure was $5.6 million, 39.08% down from the prior year.
  • Long-Term Investments for Q3 2023 was $4.4 million at vTv Therapeutics, down from $8.0 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $9.6 million in Q2 2021 and bottomed at $2.5 million in Q1 2019.
  • The 5-year median for Long-Term Investments is $5.8 million (2022), against an average of $5.4 million.
  • The largest annual shift saw Long-Term Investments soared 287.98% in 2021 before it tumbled 40.01% in 2022.
  • A 5-year view of Long-Term Investments shows it stood at $2.5 million in 2019, then surged by 171.17% to $6.7 million in 2020, then surged by 36.4% to $9.2 million in 2021, then tumbled by 39.08% to $5.6 million in 2022, then fell by 21.49% to $4.4 million in 2023.
  • Per Business Quant, the three most recent readings for VTVT's Long-Term Investments are $4.4 million (Q3 2023), $8.0 million (Q2 2023), and $7.7 million (Q1 2023).